🎉 M&A multiples are live!
Check it out!

Bicycle Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Bicycle Therapeutics and similar public comparables like Pharming, Julphar, and Benevolent AI.

Bicycle Therapeutics Overview

About Bicycle Therapeutics

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.


Founded

2009

HQ

Germany
Employees

305

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$388M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Bicycle Therapeutics Financials

Bicycle Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Bicycle Therapeutics achieved revenue of $37.9M and an EBITDA of -$177M.

Bicycle Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Bicycle Therapeutics valuation multiples based on analyst estimates

Bicycle Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $29.0M $37.9M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$182M -$177M XXX XXX XXX
EBITDA Margin -628% -467% XXX XXX XXX
Net Profit -$121M -$194M XXX XXX XXX
Net Margin -418% -512% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Bicycle Therapeutics Stock Performance

As of April 15, 2025, Bicycle Therapeutics's stock price is EUR 6 (or $6).

Bicycle Therapeutics has current market cap of EUR 412M (or $442M), and EV of -EUR 361M (or -$388M).

See Bicycle Therapeutics trading valuation data

Bicycle Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$388M $442M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Bicycle Therapeutics Valuation Multiples

As of April 15, 2025, Bicycle Therapeutics has market cap of $442M and EV of -$388M.

Bicycle Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Bicycle Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Bicycle Therapeutics and 10K+ public comps

Bicycle Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$388M XXX XXX XXX
EV/Revenue -10.2x XXX XXX XXX
EV/EBITDA 2.2x XXX XXX XXX
P/E -2.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 2.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Bicycle Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Bicycle Therapeutics Valuation Multiples

Bicycle Therapeutics's NTM/LTM revenue growth is n/a

Bicycle Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Bicycle Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Bicycle Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Bicycle Therapeutics and other 10K+ public comps

Bicycle Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 31% XXX XXX XXX XXX
EBITDA Margin -467% XXX XXX XXX XXX
EBITDA Growth -3% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 203% XXX XXX XXX XXX
R&D Expenses to Revenue 490% XXX XXX XXX XXX
Opex to Revenue 693% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Bicycle Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Bicycle Therapeutics M&A and Investment Activity

Bicycle Therapeutics acquired  XXX companies to date.

Last acquisition by Bicycle Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Bicycle Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Bicycle Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Bicycle Therapeutics

When was Bicycle Therapeutics founded? Bicycle Therapeutics was founded in 2009.
Where is Bicycle Therapeutics headquartered? Bicycle Therapeutics is headquartered in Germany.
How many employees does Bicycle Therapeutics have? As of today, Bicycle Therapeutics has 305 employees.
Who is the CEO of Bicycle Therapeutics? Bicycle Therapeutics's CEO is Dr. Kevin Lee, M.B.A..
Is Bicycle Therapeutics publicy listed? Yes, Bicycle Therapeutics is a public company listed on BER.
What is the stock symbol of Bicycle Therapeutics? Bicycle Therapeutics trades under 50BA ticker.
When did Bicycle Therapeutics go public? Bicycle Therapeutics went public in 2019.
Who are competitors of Bicycle Therapeutics? Similar companies to Bicycle Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Bicycle Therapeutics? Bicycle Therapeutics's current market cap is $442M
What is the current revenue growth of Bicycle Therapeutics? Bicycle Therapeutics revenue growth between 2023 and 2024 was 31%.
Is Bicycle Therapeutics profitable? Yes, Bicycle Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.